Weave’s Brandon Rice on Rebuilding Drug Regulation with AI @NEJMgroup

Uploaded July 2026 | Updated September 2026, 1 week ago

Brandon Rice believes that improving health care sometimes means improving the systems behind it. Through his work at Weave, he focuses on modernizing the regulatory infrastructure that helps bring new medicines to market. He discusses the challenge of organizing scientific knowledge, communicating with regulators, and navigating processes that can span more than a decade. His vision is that AI can reduce administrative burden while preserving the rigor required for patient safety and scientific progress.

Download the full transcript and subscribe to AI Grand Rounds: podbean.com/eau/pb-99ygs-1b0c111

#ai #artificialintelligence

Weave’s Brandon Rice on Rebuilding Drug Regulation with AI

$HFpEF Explained — Prevalence, New Advances, and How to Diagnose | NEJM This first episode of a three-part Double Take video miniseries on heart failure with preserved ejection fraction (HFpEF) from the New England Journal of Medicine discusses how HFpEF differs from heart failure with reduced ejection fraction, key risk factors, underlying causes, and the challenges of diagnosis. The cardiologists walk through the diagnostic evaluation, including use of the H2FPEF score to support clinical decision making. For further reading, the following articles, referenced in this video, are available at NEJM.org: Empagliflozin in Heart Failure with a Preserved Ejection Fraction (Anker et al., in the October 14, 2021, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2107038 ), Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (Kosiborod et al., in the September 21, 2023, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2306963 ), Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (Solomon et al., in the October 24, 2024, issue, https://www.nejm.org/doi/10.1056/NEJMoa2407107 ), Heart Failure with Preserved Ejection Fraction (Cannata and McDonagh, in the January 9, 2025, issue, https://www.nejm.org/doi/full/10.1056/NEJMcp2305181 ), and Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (Packer et al., in the January 30, 2025, issue, https://www.nejm.org/doi/full/10.1056/NEJMoa2410027 ). Funding for this Double Take is provided by the Doris Duke Foundation, committed to building a creative, equitable, and sustainable future. #medicaleducation #clinicalmedicine #nejm The New England Journal of Medicine is the world’s leading general medical journal. Continuously published for over 200 years, the Journal publishes peer-reviewed research along with interactive clinical content for physicians, educators, and the global medical community at NEJM.org.$

Osimertinib plus Chemotherapy in EGFR-Mutated NSCLC (FLAURA2)

Asundexian for Secondary Stroke Prevention (OCEANIC-STROKE)

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma (LITESPARK-022)

NEJM Interview: Sara Gerke on a Utah pilot program involving an AI system that autonomously renew...

NEJM Interview: Yaara Zisman-Ilani on navigating the uncertainty surrounding medication managemen...